 |
- The Cue COVID-19 Test was authorized for self-testing by the Singapore Health Sciences Authority (HSA) through its Pandemic Special Access Route (PSAR)
- The HSA authorization of the Cue COVID-19 Test is for home use in both symptomatic and asymptomatic users, ages 2 years and up
- Cue Health has partnered with Omnicell Pte Ltd to immediately begin supplying the Cue COVID-19 Test in Singapore
SAN DIEGO, Dec. 2, 2021 /PRNewswire/ -- Cue Health ("Cue") (Nasdaq: HLTH), a healthcare technology company, today announced it received Pandemic Special Access Route (PSAR) authorization from the Health Sciences Authority (HSA) for the Cue COVID-19 Test for self-testing in Singapore. The Cue COVID-19 Test is the first natively digital molecular diagnostic product ever authorized for consumer home use in Singapore. Cue's partnership with Omnicell Pte Ltd allows Cue to immediately begin supporting public sector use of the Cue COVID-19 Test.
"We are excited to bring Cue's digitally connected, in-home molecular diagnostics platform to Singaporean stakeholders and help provide immediate access to critical health information. With Cue, users will be able to make faster and more informed healthcare decisions at a time when it's needed most," said Ayub Khattak, Co-Founder and CEO of Cue. "Singapore as a country has been a thought leader in adopting innovative healthcare technologies at scale and has been a leading example for other APAC countries in the region. Cue's HSA authorization sets the foundation for broad application of the Cue platform in Singapore."
Omnicell Pte Ltd Regional Account Director Yoco Ting commented, "Testing remains an important component in Singapore's overall strategy for managing COVID-19. With the recent authorization of the Cue COVID-19 Test via the Pandemic Special Access Route, Omnicell is excited to bring forth into Singapore the technological advancement from Cue and further simplify the COVID-19 testing process by now combining the speed of rapid antigen tests with the lab-quality accuracy of PCR tests. We will continue to work closely with local authorities and Cue to further the effort in controlling COVID-19 in Singapore."
As the maker of the first and only natively digital molecular diagnostics solution available in Singapore, Cue intends to explore both public and private sector partnerships that Cue believes will further enable the complete utilization of the Cue Health Monitoring System for not only the Cue COVID-19 Test, but also Cue's future test menu and other offerings.
Last month, Cue launched its direct-to-consumer (DTC) virtual health platform in the United States, making Cue's first-of-its-kind molecular COVID-19 test available through Cue's new eCommerce site and in-app shop. Cue's new membership offering — Cue+™ — offers members 24/7 on-demand access to board certified physicians, e-prescription services, CDC-compliant test results for travel through in-app video proctoring, and same-day delivery of Cue products in a number of major markets.
About Cue Health
Cue Health (Nasdaq: HLTH) is a healthcare technology company that makes it easy for individuals to access health information and places diagnostic information at the center of care. Cue Health enables people to manage their health through real-time, actionable, and connected health information, offering individuals and their healthcare providers easy access to lab-quality diagnostics anywhere, anytime, in a device that fits in the palm of the hand. Cue Health's first-of-its-kind COVID-19 test was the first FDA-authorized molecular diagnostic test for at-home and over-the-counter use without a prescription and physician supervision. Outside the United States, Cue Health has received the CE mark in the European Union, Interim Order authorization from Health Canada, and regulatory approval from India's Central Drugs Standard Control Organisation. Cue was founded in 2010 and is headquartered in San Diego. For more information, please visit www.cuehealth.com.
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements". The words, without limitation, "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the factors discussed in the "Risk Factors" section of the Form 10-Q dated November 10, 2021 filed by Cue with the SEC. Any forward-looking statements contained in this press release are based on the current expectations of Cue's management team and speak only as of the date hereof, and Cue specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
The Cue COVID-19 Test for Home and Over The Counter (OTC) Use and the Cue COVID-19 Test (for professional use) have not been FDA cleared or approved; but have been authorized by FDA under an Emergency Use Authorization (EUA). These products have been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. The emergency use of these products is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
